Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia
Leukemia, Hairy Cell
Proto-Oncogene Proteins B-raf
A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia. (Funded by the Associazione Italiana per la Ricerca sul Cancro and others; EudraCT number, 2011-005487-13; ClinicalTrials.gov number NCT01711632.).